The surrogate outcome of progression free survival (PFS) can reliably predict overall survival (OS) in trials of immunotherapy, an Australian study has shown. Researchers at the NHMRC Clinical Trials Centre at the University of Sydney have developed a prediction model that uses 6-month PFS from the immunotherapy arm of randomised clinical trials (RCTs) to estimate ...
PFS can reliably predict overall survival in trials of immunotherapy
By Michael Woodhead
11 Sep 2020